Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split

Stock Information for TCR2 Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About TCR2 Therapeutics Inc.

Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Crescent Biopharma to Present at November Investor Conferences
Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting
Crescent Biopharma to Present at September Investor Conferences
Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer
Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million
CATALYST BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Catalyst Biosciences, Inc. - CBIO

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.